top of page
Search

EVI at World Vaccine Congress Europe 2025: Driving collaboration and innovation

  • Writer: EVI
    EVI
  • Oct 19
  • 2 min read

 The European Vaccine Initiative (EVI) was delighted to participate in the World Vaccine Congress Europe 2025 in Amsterdam, a key global gathering for leaders driving innovation across the vaccine ecosystem.

October 2025


The Partnerships & Access session during the World Vaccine Congress Europe 2025 focused on advancing vaccine development through collaboration, funding, and stakeholder engagement.


Dr Irina Meln at the “Systemic and Shifting Global Market Stressors: Navigating Funding, Partnerships and Innovation in a Volatile Era”  panel.
Dr Irina Meln at the “Systemic and Shifting Global Market Stressors: Navigating Funding, Partnerships and Innovation in a Volatile Era”  panel.

Discussions included fundraising and licensing, incubators and funding models, and strategies to overcome global market challenges. Panels explored strategic partnerships, NGO engagement, and strengthening local and global networks for clinical trials, with an emphasis on sustainable, equitable, and effective collaborations.


EVI’s Head of Innovation, Dr Irina Meln, contributed to the programme of Partnerships & Access with a presentation on “The Role of NGOs in Stakeholder Engagement”, highlighting how EVI connects academia, industry and regulators to accelerate the adoption of new technologies. For example, in the Inno4Vac project, EVI organised several stakeholder engagement meetings to address important ethics, clinical, and regulatory topics, ensuring that newly developed tools are usable in the future.


"Engaging stakeholders across academia, industry, and regulators ensures that our vaccine innovations are not only scientifically strong but ready for real-world impact.", Dr Irina Meln, Head of Innovation, EVI

Dr Irina Meln with Erta Kalanxhi, Director, Partnerships at One Health Trust.
Dr Irina Meln with Erta Kalanxhi, Director, Partnerships at One Health Trust.

Overall, the session Partnerships & Access highlighted the critical role of cross-sector partnerships in accelerating vaccine innovation and ensuring access worldwide.

It was also a great opportunity to meet like-minded colleagues, including representatives from One Health Trust, including Dr. Erta Kalanxhi, as well as TBVI, and share EVI’s vision for global health.


EVI also contributed to discussions on Europe’s strategic role in powering vaccine innovation and in addressing antimicrobial resistance (AMR). The organisation’s portfolio reflects this integrated approach, including:

  • Assessing the health and economic value of vaccines through PrIMAVeRa

  • Developing AI-based diagnostic tools in the DRAIGON project to combat AMR

  • Advancing controlled human infection models (CHIMs) such as the C. difficile model within Inno4Vac


Together, these initiatives exemplify EVI’s commitment to developing innovative models, digital tools and value assessments that strengthen vaccine research and enhance public health impact. 

 
 
bottom of page